Effectiveness of crizotinib in a patient with ALK IHC-positive/FISH-negative metastatic lung adenocarcinoma

Lung Cancer

Volumn 98, Issue , 2016, Pages 118-121

  Rosoux, A ^a   Pauwels, P ^b   Duplaquet, F ^a   D'Haene, N ^c   Weynand, B ^d   Delos, M ^e   Menon, R ^f   Heukamp, L C ^f   Thunnissen, E ^g   Ocak, S ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c ERASME HOSPITAL   (Belgium)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e CHU UCL NAMUR   (Belgium)

^f NEO New Oncology GmbH   (Germany)

^g VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

ALK; Crizotinib; Fluorescent in situ hybridization; Immunohistochemistry; Non small cell lung cancer

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CASE REPORT; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG LOBECTOMY; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SYSTEMIC THERAPY; ADENOCARCINOMA; CANCER STAGING; FATALITY; GENETICS; LUNG TUMOR; METABOLISM; METASTASIS;

ADENOCARCINOMA; ADULT; ANTINEOPLASTIC AGENTS; FATAL OUTCOME; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; NEOPLASM METASTASIS; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84974574147     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2016.06.001     Document Type: Article

References (36)

1. Camidge D.R., Bang Y.J., Kwak E.L., et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012, 13:1011-1019.
2. Kwak E.L., Bang Y.J., Camidge D.R., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 2010, 363:1693-1703.
3. Shaw A.T., Kim D.W., Nakagawa K., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 2013, 368:2385-2394.
4. Solomon B.J., Mok T., Kim D.W., et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N. Engl. J. Med. 2014, 371:2167-2177.
5. Rodig S.J., Mino-Kenudson M., Dacic S., et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin. Cancer Res. 2009, 15:5216-5223.
6. Soda M., Choi Y.L., Enomoto M., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
7. Rikova K., Guo A., Zeng Q., et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007, 131:1190-1203.
8. Takeuchi K., Choi Y.L., Togashi Y., et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin. Cancer Res. 2009, 15:3143-3149.
9. Togashi Y., Soda M., Sakata S., et al. KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PLoS One 2012, 7:e31323.
10. McLeer-Florin A., Moro-Sibilot D., Melis A., et al.Dual I.H.C. and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study. J. Thorac. Oncol. 2012, 7:348-354.
11. Selinger C.I., Rogers T.M., Russell P.A., et al. Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Mod. Pathol. 2013, 26:1545-1553.
12. Wynes M.W., Sholl L.M., Dietel M., et al. An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators. J. Thorac. Oncol. 2014, 9:631-638.
13. Peled N., Palmer G., Hirsch F.R., et al. Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer. J. Thorac. Oncol. 2012, 7:e14-16.
14. Sun J.M., Choi Y.L., Won J.K., et al. A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK. J. Thorac. Oncol. 2012, 7:e36-38.
15. Pender A., Popat S. The efficacy of crizotinib in patients with ALK-positive nonsmall cell lung cancer. Ther. Adv. Respir. Dis. 2015, 9:97-104.
16. Yi E.S., Chung J.H., Kulig K., et al. Detection of anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer and related issues in ALK inhibitor therapy: a literature review. Mol. Diagn. Ther. 2012, 16:143-150.
17. Rogers T.M., Russell P.A., Wright G., et al. Comparison of methods in the detection of ALK and ROS1 rearrangements in lung cancer. J. Thorac. Oncol. 2015, 10:611-618.
18. Wallander M.L., Geiersbach K.B., Tripp S.R., et al. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing. Arch. Pathol. Lab. Med. 2012, 136:796-803.
19. Li T., Maus M.K., Desai S.J., et al. Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays. J. Thorac. Oncol. 2014, 9:18-25.
20. Tuononen K., Sarhadi V.K., Wirtanen A., et al. Targeted resequencing reveals ALK fusions in non-small cell lung carcinomas detected by FISH, immunohistochemistry, and real-time RT-PCR: a comparison of four methods. Biomed. Res. Int. 2013, 2013:757490.
21. Ali G., Proietti A., Pelliccioni S., et al. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment. Arch. Pathol. Lab. Med. 2014, 138:1449-1458.
22. Blackhall F.H., Peters S., Bubendorf L., et al. Prevalence and clinical outcomes for patients with ALK-positive resected stage I-III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project. J. Clin. Oncol. 2014, 32:2780-2787.
23. Cabillic F., Gros A., Dugay F., et al.Parallel F.I.S.H. and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances. J. Thorac. Oncol. 2014, 9:295-306.
24. B.C. tJLCS Second notice of the results on IHC-FISH discordant cases (Japanese).
25. Ren S., Hirsch F.R., Varella-Garcia M., et al. Atypical negative ALK break-apart FISH harboring a crizotinib-responsive ALK rearrangement in non-small-cell lung cancer. J. Thorac. Oncol. 2014, 9:e21-23.
26. Pekar-Zlotin M., Hirsch F.R., Soussan-Gutman L., et al. Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer. Oncologist 2015, 20:316-322.
27. Yatabe Y. ALK FISH and IHC: you cannot have one without the other. J. Thorac. Oncol. 2015, 10:548-550.
28. Thunnissen E., Bubendorf L., Dietel M., et al. EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch. 2012, 461:245-257.
29. Camidge D.R., Skokan M., Kiatsimkul P., et al. Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: implications for ALK inhibitor therapy. Cancer 2013, 119:3968-3975.
30. Ilie M.I., Bence C., Hofman V., et al. Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK 'borderline'-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies. Ann. Oncol. 2015, 26:238-244.
31. von Laffert M., Stenzinger A., Hummel M., et al. ALK-FISH borderline cases in non-small cell lung cancer: implications for diagnostics and clinical decision making. Lung Cancer 2015, 90:465-471.
32. Togashi Y., Mizuuchi H., Kobayashi Y., et al. An activating ALK gene mutation in ALK IHC-positive/FISH-negative nonsmall-cell lung cancer. Ann. Oncol. 2015, 26:1800-1801.
33. Wiesner T., Lee W., Obenauf A.C., et al. Alternative transcription initiation leads to expression of a novel ALK isoform in cancer. Nature 2015, 526:453-457.
34. Laffert M.V., Warth A., Penzel R., et al. Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC): results of a multi-centre ALK-testing. Lung Cancer 2013, 81:200-206.
35. von Laffert M., Penzel R., Schirmacher P., et al.Multicenter A.L.K. testing in non-small-cell lung cancer: results of a round robin test. J. Thorac. Oncol. 2014, 9:1464-1469.
36. Camidge D.R., Theodoro M., Maxson D.A., et al. Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer. Cancer 2012, 118:4486-4494.